Overall, 19 patients received osimertinib plus necitumumab; at data cutoff (April 18, 2023), all patients had discontinued treatment. The ORR was 11% (80% CI, 3 to 26); two patients had a confirmed ...

Guidance programme Guidance programme Antimicrobial prescribing guidelines (20) Cancer service guidelines (8) Clinical guidelines (226) COVID-19 rapid guidelines (3) Diagnostics guidance (50) Health ...

In a retrospective study of 4 trials of patients with nonsmall-cell lung cancer, treatment with necitumumab significantly increased the risk of VTE compared with the control arm (9.9% versus 6.6%; RR, ...

The higher-order structure (HOS) of therapeutic monoclonal antibodies is one of the important quality characteristics in terms of efficacy and safety. However, the HOS of therapeutic monoclonal ...

Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer: TA411: 28 September 2016: 28 September 2016: Radium-223 dichloride for treating hormone-relapsed prostate cancer ...

Phase III SQUIRE Trial in Patients With NSCLC Treated With Necitumumab. Martin Reck, MD, PhD. July 28th 2015. Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the ...